Medtronic’s In.Pact AV Drug-Coated Balloon Effectively Treats Hemodialysis Access Lesions In Trial
Executive Summary
The In.Pact AV paclitaxel-coated balloon outperformed plain angioplasty balloons in the IN.PACT AV Access trial, the first large, multi-center randomized trial comparing a drug-coated balloon to standard balloon angioplasty in the treatment of hemodialysis arteriovenous access stenoses.
You may also be interested in...
Medtronic Adds Avenu’s Percutaneous Fistula Technology
Avenu’s Ellipsys vascular access system is an ultrasound-guided catheter to create a durable arteriovenous fistula for patients undergoing dialysis.
Global Approvals Snapshot: November 2019
November’s approvals include the US FDA approval of Medtronic’s In.Pact AV paclitaxel-coated balloon, for the treatment of arteriovenous access in patients with end-stage renal disease, and a CE mark that expands the indication for Edwards’ Sapien 3 TAVR device to include patients at low-risk during surgery.
Newer Data Fades Paclitaxel Risk, Physician Group Says
A meta-analysis that seemed to show an increased mortality risk tied to paclitaxel-coated balloons and stents sent shockwaves through the device industry last year. But a more complete data review funded by nonprofit group VIVA Physicians may show that the issue has been overestimated.